Shingles Vaccine Market
Shingles Vaccine Market Study by Recombinant Vaccines, Live Attenuated Vaccines for Shingles, Zostavax, and Sky Zoster from 2024 to 2034
Analysis of Shingles Vaccine Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Shingles Vaccine Market Outlook (2024 to 2034)
Revenue from the global shingles vaccine market size is estimated at US$ 2.71 billion in 2024. The market is analyzed to climb to a value of US$ 5.97 billion by the end of 2034, expanding at a CAGR of 8.2% from 2024 to 2034.
Shingles is a viral infection that leads to a painful rash. Shingles can appear anywhere on the body. It usually appears as a single band of blisters around the torso, either on the left or right side.
The varicella-zoster virus, which also causes chickenpox, is the source of shingles. The virus that causes chickenpox remains in your body for the duration of your life. The virus may reactivate as shingles years later. There is no risk to life from shingles but the pain can be excruciating. Vaccines can reduce the chance of developing shingles. Treatment for shingles early on can reduce the duration of the infection and lower the risk of complications.
Key Market Growth Drivers
- Increased risk of developing shingles, especially in those 60 years of age and older, as well as improvements in healthcare facilities in developed countries, are the main drivers of shingles vaccine market growth.
- Shingrix prevents shingles from occurring again if one has already had the illness. There is no set amount of time one needs to wait to receive the Shingrix vaccine after developing shingles, but generally, it is advised to wait until the rash has healed before receiving the shot.
- Trend toward innovative recombinant vaccines is expected to fuel market expansion.
- Since 2006, adults over 60 years of age were advised to receive a shingles vaccination by the United States Advisory Committee on Immunization Practices.
- Due to the vaccine's high efficacy, the Centers for Disease Control and Prevention (CDC) recommended Shingrix over Zostavax in January 2018 to prevent Shingles.
- The National Center for Biotechnology Information estimates that in the next 10 years, there will be 278 million cases of herpes zoster worldwide if there is no shingles vaccine. While there are several antiviral treatments for shingles, including acyclovir and valacyclovir, immunization against the herpes zoster virus becomes crucial in patients with compromised immune systems.
- Postherpetic neuralgia (PHN) is not responsive to antiviral treatment. Therefore, during the projected period, the development of an effective vaccine is projected to serve as a driving force for the expansion of the shingles vaccine market size.
| Report Attribute | Detail |
|---|---|
| Shingles Vaccine Market Size (2024E) | US$ 2.71 Billion |
| Forecasted Market Value (2034F) | US$ 5.97 Billion |
| Global Market Growth Rate (2024 to 2034) | 8.2% CAGR |
| North America Market Share (2024E) | 67.5% |
| East Asia Market Share (2024E) | 9.1% |
| Revenue from Sales of Recombinant Vaccines (2024E) | US$ 2.29 Billion |
| Key Companies Profiled | Cipla Inc.; Pfizer Inc.; Merck & Co., Inc.; SK Chemicals; Vaccitech; CanSinoBIO; Green Cross Corp.; GlaxoSmithKline Plc.; GeneOne Life Science. |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Why is There Heightened Need for Herpes Zoster Vaccines for the Elderly?
“Increased Risks of Stroke, Pneumonia, and Encephalitis from Shingles among Older Adults”
Due to weakened immune systems brought on by aging, older adults are more vulnerable to developing shingles. Adults over 60 years of age account for half of all shingles cases globally.
- The risk of developing shingles increases over the age of 60, affecting one in three people at some point in their lives, according to the Centers for Disease Control and Prevention (CDC). The immune systems of about 30% of patients admitted to hospitals with shingles are found to be compromised.
Shingles cause additional health problems in older adults, including a higher risk of stroke and other complications such as pneumonia and encephalitis. Consequently, to treat the elderly population, a herpes zoster vaccine that is both safe and affordable is needed.
What are the Factors Affecting the Uptake of Shingles Vaccines?
“Lack of Access to Education Programs Tailored for Particular Demographics”
Significance of the shingles vaccine is not widely understood by the general public. Knowledge about shingles and the importance of immunization varies significantly across the globe. In certain low- and middle-income countries, there may be insufficient public education campaigns regarding shingles and preventive measures.
Limited awareness of vaccines and their advantages leads to low vaccine literacy. Communities with low health literacy often lack awareness about the risks of shingles or the potential benefits of vaccination. Certain communities do not have access to education programs designed with particular demographics in mind, such as older adults who are at risk, in mind. Programs for targeted education do not exist in isolated areas or towns with few medical facilities.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Insights
North America is a key market for shingles vaccine providers due to increasing investments in healthcare and a growing geriatric population. Europe is adopting similar measures and building up its healthcare system in tandem. Asia Pacific has room to grow as a result of a growing aging population. Need for vaccines is largely driven by the rising incidence of shingles and initiatives to avoid post-herpetic neuralgia. The introduction of health campaigns and focus on easier access to vaccinations are key shingles vaccine market trends.
Will Aging Population Contribute to Increasing Vaccination Rates in the United States?
“Rising Immunization Recommendations for Older Adults”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 1.78 Billion |
| Growth Rate (2024 to 2034) | 5.8% CAGR |
| Projected Value (2034F) | US$ 3.14 Billion |
Aging is associated with decreased immune function, making people more susceptible to infections. The varicella-zoster virus, which causes shingles, reactivates due in part to the weakened immune systems of the elderly.
- According to estimates from the CDC, one in three Americans will get shingles at some point in their lives which is expected to drive the market in the country.
More than 99% of people in the United States who are 40 years of age and older have symptoms consistent with a history of varicella infection, putting them at risk of developing shingles. As people are aging, vaccination rates also tend to increase, particularly for immunizations recommended for older adults. Healthcare reports indicate that the uptake of the shingles vaccine is rising as vaccination recommendations and awareness campaigns target older populations.
How is Rapid Expansion of Healthcare Infrastructure Influencing Market Growth in China?
“Investments in Healthcare Infrastructure Enhancing Vaccine Accessibility”
| Attribute | China |
|---|---|
| Market Value (2024E) | US$ 132 Million |
| Growth Rate (2024 to 2034) | 11.4% CAGR |
| Projected Value (2034F) | US$ 390 Million |
Increasing burden of infectious diseases, including shingles, is prompting healthcare providers to focus on implementing preventive measures such as vaccination. The expansion of healthcare infrastructure, including vaccination clinics and distribution networks, is helping improve access to vaccines across different parts of China. This infrastructure development contributes to the growing availability and uptake of the shingles vaccine. Government-led vaccination campaigns and subsidies for shingles vaccines are influencing the adoption of the shingles vaccine.
- GlaxoSmithKline (GSK) recently entered into an exclusive partnership with Chongqing Zhifei Biological Products to distribute the Shingrix vaccine in China. Zhifei has agreed to pay £2.5 billion (US$ 3.05 billion) for the exclusive distribution rights from 2024 to 2026 along with a certain volume of the vaccine. This partnership is expected to expedite the availability of Shingrix, since Zhifei can provide about 30,000 vaccination locations throughout China.
Category-wise Insights
The market is categorized into Shingrix, Zostavax, and Sky Zoster, of which Shingrix is set to hold a key shingles vaccine market share of 84.7% in 2024. In terms of end users, private and government healthcare settings are responsible for distributing vaccines to more people.
What is Driving Increasing Demand for Shingrix Vaccines Globally?
“Efficacy of Shingrix in Preventing Herpes Zoster and Post-Herpetic Neuralgia”
| Attribute | Shingrix |
|---|---|
| Segment Value (2024E) | US$ 2.29 Billion |
| Growth Rate (2024 to 2034) | 8.3% CAGR |
| Projected Value (2034F) | US$ 5.1 Billion |
Shingrix is an adjuvant subunit vaccine that includes recombinant VZV glycoprotein E (gE). Those above 50 years use it to prevent herpes zoster (shingles) and post-herpetic neuralgia, which is chronic nerve pain that occurs after shingles.
Since these vaccinations are very effective and have fewer side effects, Shingrix is expected to hold a significant share of the market. Growing demand for these vaccines is driven by rising awareness of the disease's consequences and the growing number of countries that have approved Shingrix for use as a vaccine.
Why Do Government Healthcare Settings Account for a High Number of Shingles Vaccinations?
“Collaborations Between Governments and Vaccine Providers”
| Attribute | Government Healthcare Settings |
|---|---|
| Segment Value (2024E) | US$ 1.6 Billion |
| Growth Rate (2024 to 2034) | 8.5% CAGR |
| Projected Value (2034F) | US$ 3.62 Billion |
Government policies encouraging adult vaccination programs, particularly for the elderly, are helping boost the adoption of shingles vaccines. For example, the Australian Government is collaborating closely with state and territory governments to ensure that Shingrix doses are distributed fairly and appropriately to meet demand.
To guarantee that the local supply is managed fairly and effectively, individual states and territories oversee the distribution of vaccines to local providers. Governments across the world are closely collaborating with vaccine suppliers to investigate potential ways to expedite vaccination in their respective countries.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
Key players in the shingles vaccine market are largely aiming at setting up manufacturing facilities, creating more order, and investing in research to develop more effective vaccines.
- Pfizer and BioNTech started their third partnership in January 2022, with Pfizer contributing US$ 225 million. The goal of this collaborative endeavor is to apply RNA technology to the creation of a shingles vaccine. The creation of an effective and tolerable mRNA-based shingles vaccine is the main objective of this collaboration. The development costs of the vaccine will be split between the two companies, and clinical trials are expected to start in the second quarter of 2022.
- GlaxoSmithKline in June 2021 announced that it would relaunch its shingles vaccine after seeing a drop in sales due to disruptions in COVID-19 vaccine rollouts. The company also sought to establish itself as the world's top vaccine producer.
Fact.MR provides detailed information about the price points of key providers of shingles vaccines positioned across the world, sales growth, production capacity, and speculative technological expansion, in this new market report.
Segmentation of Shingles Vaccine Market Research
-
By Type :
- Shingrix
- Zostavax
- Sky Zoster
-
Vaccine Type :
- Recombinant Vaccines
- Live Attenuated Vaccines
-
By End User :
- Government Healthcare Settings
- Private Healthcare Settings
-
By Region :
- North America
- Western Europe
- Eastern Europe
- Latin America
- East Asia
- South Asia & Pacific
- Middle East & Africa
Table of Content
- 1. Executive Summary
- 2. Industry Introduction, including Taxonomy and Market Definition
- 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
- 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections
- 5. Pricing Analysis
- 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034
- 6.1. Type
- 6.2. Vaccine Type
- 6.3. End User
- 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Type
- 7.1. Shingrix
- 7.2. Zostavax
- 7.3. Sky Zoster
- 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Vaccine Type
- 8.1. Recombinant Vaccines
- 8.2. Live Attenuated Vaccines
- 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by End User
- 9.1. Government Healthcare Settings
- 9.2. Private Healthcare Settings
- 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region
- 10.1. North America
- 10.2. Latin America
- 10.3. Western Europe
- 10.4. Eastern Europe
- 10.5. East Asia
- 10.6. South Asia & Pacific
- 10.7. Middle East & Africa
- 11. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 12. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 13. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 14. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 15. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 16. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 17. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 18. Sales Forecast 2024 to 2034 by Type, Vaccine Type, End User, and Region for 30 Countries
- 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
- 20. Company Profile
- 20.1. Cipla Inc.
- 20.2. Pfizer Inc.
- 20.3. Merck & Co., Inc.
- 20.4. SK Chemicals
- 20.5. Vaccitech
- 20.6. CanSinoBIO
- 20.7. Green Cross Corp.
- 20.8. GlaxoSmithKline Plc.
- 20.9. GeneOne Life Science
- 21. Assumptions and Acronyms Typed
- 22. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Value (US$ Mn) Analysis, by Type, 2019 to 2023
Table 02: Global Market Value (US$ Mn) Analysis, by Type, 2024 to 2034
Table 03: Global Market Value (US$ Mn) Opportunity Analysis, by Type, 2024 to 2034
Table 04: Global Market Value (US$ Mn) Analysis, by Vaccine Type, 2019 to 2023
Table 05: Global Market Value (US$ Mn) Analysis, by Vaccine Type, 2024 to 2034
Table 06: Global Market Value (US$ Mn) Opportunity Analysis, by Vaccine Type, 2024 to 2034
Table 07: Global Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 08: Global Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 09: Global Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 10: Global Market Value (US$ Mn) Analysis, by Region, 2019 to 2023
Table 11: Global Market Value (US$ Mn) Analysis, by Region, 2024 to 2034
Table 12: Global Market Value (US$ Mn) Opportunity Analysis, by Region, 2024 to 2034
Table 13: North America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 14: North America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 15: North America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 16: North America Market Value (US$ Mn) Analysis, by Type, 2019 to 2023
Table 17: North America Market Value (US$ Mn) Analysis, by Type, 2024 to 2034
Table 18: North America Market Value (US$ Mn) Opportunity Analysis, by Type, 2024 to 2034
Table 19: North America Market Value (US$ Mn) Analysis, by Vaccine Type, 2019 to 2023
Table 20: North America Market Value (US$ Mn) Analysis, by Vaccine Type, 2024 to 2034
Table 21: North America Market Value (US$ Mn) Opportunity Analysis, by Vaccine Type, 2024 to 2034
Table 22: North America Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 23: North America Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 24: North America Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 25: Latin America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 26: Latin America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 27: Latin America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 28: Latin America Market Value (US$ Mn) Analysis, by Type, 2019 to 2023
Table 29: Latin America Market Value (US$ Mn) Analysis, by Type, 2024 to 2034
Table 30: Latin America Market Value (US$ Mn) Opportunity Analysis, by Type, 2024 to 2034
Table 31: Latin America Market Value (US$ Mn) Analysis, by Vaccine Type, 2019 to 2023
Table 32: Latin America Market Value (US$ Mn) Analysis, by Vaccine Type, 2024 to 2034
Table 33: Latin America Market Value (US$ Mn) Opportunity Analysis, by Vaccine Type, 2024 to 2034
Table 34: Latin America Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 35: Latin America Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 36: Latin America Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 37: Western Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 38: Western Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 39: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 40: Western Europe Market Value (US$ Mn) Analysis, by Type, 2019 to 2023
Table 41: Western Europe Market Value (US$ Mn) Analysis, by Type, 2024 to 2034
Table 42: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Type, 2024 to 2034
Table 43: Western Europe Market Value (US$ Mn) Analysis, by Vaccine Type, 2019 to 2023
Table 44: Western Europe Market Value (US$ Mn) Analysis, by Vaccine Type, 2024 to 2034
Table 45: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Vaccine Type, 2024 to 2034
Table 46: Western Europe Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 47: Western Europe Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 48: Western Europe Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 49: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 50: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 51: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 52: Eastern Europe Market Value (US$ Mn) Analysis, by Type, 2019 to 2023
Table 53: Eastern Europe Market Value (US$ Mn) Analysis, by Type, 2024 to 2034
Table 54: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Type, 2024 to 2034
Table 55: Eastern Europe Market Value (US$ Mn) Analysis, by Vaccine Type, 2019 to 2023
Table 56: Eastern Europe Market Value (US$ Mn) Analysis, by Vaccine Type, 2024 to 2034
Table 57: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Vaccine Type, 2024 to 2034
Table 58: Eastern Europe Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 59: Eastern Europe Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 60: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 61: East Asia Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 62: East Asia Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 63: East Asia Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 64: East Asia Market Value (US$ Mn) Analysis, by Type, 2019 to 2023
Table 65: East Asia Market Value (US$ Mn) Analysis, by Type, 2024 to 2034
Table 66: East Asia Market Value (US$ Mn) Opportunity Analysis, by Type, 2024 to 2034
Table 67: East Asia Market Value (US$ Mn) Analysis, by Vaccine Type, 2019 to 2023
Table 68: East Asia Market Value (US$ Mn) Analysis, by Vaccine Type, 2024 to 2034
Table 69: East Asia Market Value (US$ Mn) Opportunity Analysis, by Vaccine Type, 2024 to 2034
Table 70: East Asia Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 71: East Asia Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 72: East Asia Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 73: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 74: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 75: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 76: South Asia & Pacific Market Value (US$ Mn) Analysis, by Type, 2019 to 2023
Table 77: South Asia & Pacific Market Value (US$ Mn) Analysis, by Type, 2024 to 2034
Table 78: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Type, 2024 to 2034
Table 79: South Asia & Pacific Market Value (US$ Mn) Analysis, by Vaccine Type, 2019 to 2023
Table 80: South Asia & Pacific Market Value (US$ Mn) Analysis, by Vaccine Type, 2024 to 2034
Table 81: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Vaccine Type, 2024 to 2034
Table 82: South Asia & Pacific Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 83: South Asia & Pacific Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 84: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 85: MEA Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 86: MEA Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 87: MEA Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 88: MEA Market Value (US$ Mn) Analysis, by Type, 2019 to 2023
Table 89: MEA Market Value (US$ Mn) Analysis, by Type, 2024 to 2034
Table 90: MEA Market Value (US$ Mn) Opportunity Analysis, by Type, 2024 to 2034
Table 91: MEA Market Value (US$ Mn) Analysis, by Vaccine Type, 2019 to 2023
Table 92: MEA Market Value (US$ Mn) Analysis, by Vaccine Type, 2024 to 2034
Table 93: MEA Market Value (US$ Mn) Opportunity Analysis, by Vaccine Type, 2024 to 2034
Table 94: MEA Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 95: MEA Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 96: MEA Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 02: Global Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 03: Global Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 04: Global Market Incremental $ Opportunity, 2024 to 2034
Figure 05: Global Market Share and BPS Analysis by Type, 2024 & 2034
Figure 06: Global Market Y-o-Y Growth Projections by Type, 2024 to 2034
Figure 07: Global Market Attractiveness Analysis by Type, 2024 to 2034
Figure 08: Global Market Share and BPS Analysis by Vaccine Type, 2024 & 2034
Figure 09: Global Market Y-o-Y Growth Projections by Vaccine Type, 2024 to 2034
Figure 10: Global Market Attractiveness Analysis by Vaccine Type, 2024 to 2034
Figure 11: Global Market Share and BPS Analysis by End User, 2024 & 2034
Figure 12: Global Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 13: Global Market Attractiveness Analysis by End User, 2024 to 2034
Figure 14: Global Market Share and BPS Analysis by Region, 2024 & 2034
Figure 15: Global Market Y-o-Y Growth Projections by Region, 2024 to 2034
Figure 16: Global Market Attractiveness Analysis by Region, 2024 to 2034
Figure 17: North America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 18: North America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 19: North America Market Value Y-o-Y Growth and Forecast, 2034
Figure 20: North America Market Incremental $ Opportunity, 2024 to 2034
Figure 21: North America Market Share Analysis by Country, 2024 & 2034
Figure 22: North America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 23: North America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 24: North America Market Share and BPS Analysis by Type, 2024 & 2034
Figure 25: North America Market Y-o-Y Growth Projections by Type, 2024 to 2034
Figure 26: North America Market Attractiveness Analysis by Type, 2024 to 2034
Figure 27: North America Market Share and BPS Analysis by Vaccine Type, 2024 & 2034
Figure 28: North America Market Y-o-Y Growth Projections by Vaccine Type, 2024 to 2034
Figure 29: North America Market Attractiveness Analysis by Vaccine Type, 2024 to 2034
Figure 30: North America Market Share and BPS Analysis by End User, 2024 & 2034
Figure 31: North America Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 32: North America Market Attractiveness Analysis by End User, 2024 to 2034
Figure 33: Latin America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 34: Latin America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 35: Latin America Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 36: Latin America Market Incremental $ Opportunity, 2024 to 2034
Figure 37: Latin America Market Share Analysis by Country, 2024 & 2034
Figure 38: Latin America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 39: Latin America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 40: Latin America Market Share and BPS Analysis by Type, 2024 & 2034
Figure 41: Latin America Market Y-o-Y Growth Projections by Type, 2024 to 2034
Figure 42: Latin America Market Attractiveness Analysis by Type, 2024 to 2034
Figure 43: Latin America Market Share and BPS Analysis by Vaccine Type, 2024 & 2034
Figure 44: Latin America Market Y-o-Y Growth Projections by Vaccine Type, 2024 to 2034
Figure 45: Latin America Market Attractiveness Analysis by Vaccine Type, 2024 to 2034
Figure 46: Latin America Market Share and BPS Analysis by End User, 2024 & 2034
Figure 47: Latin America Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 48: Latin America Market Attractiveness Analysis by End User, 2024 to 2034
Figure 49: Western Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 50: Western Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 51: Western Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 52: Western Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 53: Western Europe Market Share Analysis by Country, 2024 & 2034
Figure 54: Western Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 55: Western Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 56: Western Europe Market Share and BPS Analysis by Type, 2024 & 2034
Figure 57: Western Europe Market Y-o-Y Growth Projections by Type, 2024 to 2034
Figure 58: Western Europe Market Attractiveness Analysis by Type, 2024 to 2034
Figure 59: Western Europe Market Share and BPS Analysis by Vaccine Type, 2024 & 2034
Figure 60: Western Europe Market Y-o-Y Growth Projections by Vaccine Type, 2024 to 2034
Figure 61: Western Europe Market Attractiveness Analysis by Vaccine Type, 2024 to 2034
Figure 62: Western Europe Market Share and BPS Analysis by End User, 2024 & 2034
Figure 63: Western Europe Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 64: Western Europe Market Attractiveness Analysis by End User, 2024 to 2034
Figure 66: Eastern Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 67: Eastern Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 68: Eastern Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 69: Eastern Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 70: Eastern Europe Market Share Analysis by Country, 2024 & 2034
Figure 71: Eastern Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 72: Eastern Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 73: Eastern Europe Market Share and BPS Analysis by Type, 2024 & 2034
Figure 74: Eastern Europe Market Y-o-Y Growth Projections by Type, 2024 to 2034
Figure 75: Eastern Europe Market Attractiveness Analysis by Type, 2024 to 2034
Figure 76: Eastern Europe Market Share and BPS Analysis by Vaccine Type, 2024 & 2034
Figure 77: Eastern Europe Market Y-o-Y Growth Projections by Vaccine Type, 2024 to 2034
Figure 78: Eastern Europe Market Attractiveness Analysis by Vaccine Type, 2024 to 2034
Figure 79: Eastern Europe Market Share and BPS Analysis by End User, 2024 & 2034
Figure 80: Eastern Europe Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 81: Eastern Europe Market Attractiveness Analysis by End User, 2024 to 2034
Figure 82: East Asia Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 83: East Asia Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 84: East Asia Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 85: East Asia Market Incremental $ Opportunity, 2024 to 2034
Figure 86: East Asia Market Share Analysis by Country, 2024 & 2034
Figure 87: East Asia Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 88: East Asia Market Attractiveness Analysis by Country, 2024 to 2034
Figure 89: East Asia Market Share and BPS Analysis by Type, 2024 & 2034
Figure 90: East Asia Market Y-o-Y Growth Projections by Type, 2024 to 2034
Figure 91: East Asia Market Attractiveness Analysis by Type, 2024 to 2034
Figure 92: East Asia Market Share and BPS Analysis by Vaccine Type, 2024 & 2034
Figure 93: East Asia Market Y-o-Y Growth Projections by Vaccine Type, 2024 to 2034
Figure 94: East Asia Market Attractiveness Analysis by Vaccine Type, 2024 to 2034
Figure 95: East Asia Market Share and BPS Analysis by End User, 2024 & 2034
Figure 96: East Asia Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 97: East Asia Market Attractiveness Analysis by End User, 2024 to 2034
Figure 98: South Asia & Pacific Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 99: South Asia & Pacific Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 100: South Asia & Pacific Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 101: South Asia & Pacific Market Incremental $ Opportunity, 2024 to 2034
Figure 102: South Asia & Pacific Market Share Analysis by Country, 2024 & 2034
Figure 103: South Asia & Pacific Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 104: South Asia & Pacific Market Attractiveness Analysis by Country, 2024 to 2034
Figure 105: South Asia & Pacific Market Share and BPS Analysis by Type, 2024 & 2034
Figure 106: South Asia & Pacific Market Y-o-Y Growth Projections by Type, 2024 to 2034
Figure 107: South Asia & Pacific Market Attractiveness Analysis by Type, 2024 to 2034
Figure 108: South Asia & Pacific Market Share and BPS Analysis by Vaccine Type, 2024 & 2034
Figure 109: South Asia & Pacific Market Y-o-Y Growth Projections by Vaccine Type, 2024 to 2034
Figure 110: South Asia & Pacific Market Attractiveness Analysis by Vaccine Type, 2024 to 2034
Figure 111: South Asia & Pacific Market Share and BPS Analysis by End User, 2024 & 2034
Figure 112: South Asia & Pacific Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 113: South Asia & Pacific Market Attractiveness Analysis by End User, 2024 to 2034
Figure 114: MEA Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 115: MEA Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 116: MEA Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 117: MEA Market Incremental $ Opportunity, 2024 to 2034
Figure 118: MEA Market Share Analysis by Country, 2024 & 2034
Figure 119: MEA Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 120: MEA Market Attractiveness Analysis by Country, 2024 to 2034
Figure 121: MEA Market Share and BPS Analysis by Type, 2024 & 2034
Figure 122: MEA Market Y-o-Y Growth Projections by Type, 2024 to 2034
Figure 123: MEA Market Attractiveness Analysis by Type, 2024 to 2034
Figure 124: MEA Market Share and BPS Analysis by Vaccine Type, 2024 & 2034
Figure 125: MEA Market Y-o-Y Growth Projections by Vaccine Type, 2024 to 2034
Figure 126: MEA Market Attractiveness Analysis by Vaccine Type, 2024 to 2034
Figure 127: MEA Market Share and BPS Analysis by End User, 2024 & 2034
Figure 128: MEA Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 129: MEA Market Attractiveness Analysis by End User, 2024 to 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How big is the shingles vaccine market?
The global market for shingles vaccines is expected to be valued at US$ 2.71 billion in 2024.
What are the sales projections for shingles vaccine for the decade?
The shingles vaccine market is forecasted to expand at a CAGR of 8.2% to reach US$ 5.97 billion by 2034.
Which country has a significant market for shingles vaccines?
Revenue from shingles vaccines in the United States is projected to reach US$ 1.78 billion in 2024.
What are sales projections for the market in China?
The market in China is estimated to reach a value of US$ 132 million in 2024.
Which end user accounts for significant sales of shingles vaccine?
Government healthcare settings are set to hold a market share of 59.2% in 2024 and generate revenue of US$ 1.6 billion.
What is the share of Japan in the East Asia market?
Japan accounts for a market share of 30% in East Asia in 2024.
Who are the key manufacturers of shingles vaccines?
CanSinoBIO, Green Cross Corp, GlaxoSmithKline plc. and GeneOne Life Science are some of the key players in the market.
Shingles Vaccine Market